HRP20240215T1 - Sredstva sa visokim afinitetom za ciljani učinak na membranski antigen specifičan za prostatu za endoradioterapiju raka prostate - Google Patents
Sredstva sa visokim afinitetom za ciljani učinak na membranski antigen specifičan za prostatu za endoradioterapiju raka prostate Download PDFInfo
- Publication number
- HRP20240215T1 HRP20240215T1 HRP20240215TT HRP20240215T HRP20240215T1 HR P20240215 T1 HRP20240215 T1 HR P20240215T1 HR P20240215T T HRP20240215T T HR P20240215TT HR P20240215 T HRP20240215 T HR P20240215T HR P20240215 T1 HRP20240215 T1 HR P20240215T1
- Authority
- HR
- Croatia
- Prior art keywords
- group
- image
- compound
- cell
- tumors
- Prior art date
Links
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 title claims 8
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 title claims 8
- 206010060862 Prostate cancer Diseases 0.000 title 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 title 1
- -1 p-methoxybenzyl Chemical group 0.000 claims 22
- 210000004027 cell Anatomy 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 12
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 239000002738 chelating agent Substances 0.000 claims 8
- 238000000034 method Methods 0.000 claims 7
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 6
- 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 claims 6
- 125000006239 protecting group Chemical group 0.000 claims 6
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 6
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 6
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 6
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 3
- DCERHCFNWRGHLK-UHFFFAOYSA-N C[Si](C)C Chemical compound C[Si](C)C DCERHCFNWRGHLK-UHFFFAOYSA-N 0.000 claims 3
- 125000000732 arylene group Chemical group 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 3
- 125000002993 cycloalkylene group Chemical group 0.000 claims 3
- AWJUIBRHMBBTKR-UHFFFAOYSA-N iso-quinoline Natural products C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 claims 3
- 150000002537 isoquinolines Chemical class 0.000 claims 3
- 125000005647 linker group Chemical group 0.000 claims 3
- 239000002184 metal Substances 0.000 claims 3
- 229910052751 metal Inorganic materials 0.000 claims 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 3
- 150000003222 pyridines Chemical class 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000003107 substituted aryl group Chemical group 0.000 claims 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 3
- 150000003536 tetrazoles Chemical class 0.000 claims 3
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 229910052702 rhenium Inorganic materials 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 229910052689 Holmium Inorganic materials 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 229910052772 Samarium Inorganic materials 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 229910052782 aluminium Inorganic materials 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 229910052802 copper Inorganic materials 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 229910052733 gallium Inorganic materials 0.000 claims 1
- 210000004602 germ cell Anatomy 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 229910052738 indium Inorganic materials 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 229910052745 lead Inorganic materials 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000037841 lung tumor Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000028591 pheochromocytoma Diseases 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 210000005267 prostate cell Anatomy 0.000 claims 1
- 208000023958 prostate neoplasm Diseases 0.000 claims 1
- 229910052706 scandium Inorganic materials 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- 229910052727 yttrium Inorganic materials 0.000 claims 1
- 229910052726 zirconium Inorganic materials 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
Claims (10)
1. Spoj formule (I):
[image]
naznačen time, što:
Z je tetrazol ili CO2Q;
Q je H ili protektivna grupa, pri čemu je protektivna grupa odabrana iz grupe koja se sastoji od benzila, p-metoksibenzila (PMB), tercijarnog butila (t-Bu), metoksimetila (MOM), metoksietoksimetila (MEM), metiltiometila (MTM), tetrahidropiranila (THP), tetrahidrofuranila (THF), benziloksimetila (BOM), trimetilsilila (TMS), trietilsilila (TES), t-butildimetilsilila (TBDMS) i trifenilmetila (tritil, Tr);
m je cijeli broj odabran iz grupe koja se sastoji od 1, 2, 3, 4 i 5;
R je -CH2-R1;
R1 je odabran iz grupe koja se sastoji od supstituiranog arila, supstituiranog piridina i nesupstituiranog izokinolina;
L je linker odabran iz grupe koja se sastoji od C1-C6 alkilena i C3-C6 cikloalkilena, i arilena;
W je odabran iz grupe koja se sastoji od -NR2-(C=O)-, -NR2-(C=S)-, -(C=O)-NR2- i -(C=S)-NR2-; pri čemu u svakom pojavljivanju L i W mogu biti isti ili različiti;
R2 je H ili C1-C4 alkil;
n je cijeli broj odabran iz grupe koja se sastoji od 1, 2 i 3;
Ch je kelirajuće sredstvo odabrano iz grupe koja se sastoji od:
[image]
[image]
[image]
gdje navedeno kelirajuće sredstvo sadrži metal ili radiometal;
i njegove farmaceutski prihvatljive soli.
2. Spoj prema patentnom zahtjevu 1, naznačen time što je R1 odabran iz grupe koja se sastoji od:
[image]
gdje je X nezavisno Br ili I.
3. Spoj prema bilo kojem od patentnih zahtjeva 1-2, naznačeno time, što kelirajuće sredstvo sadrži metal odabran iz grupe koja se sastoji od: Y, Lu, Tc, Zr, In, Sm, Re, Cu, Pb, Ac, Bi, Al, Ga, Re, Ho i Sc, gdje je poželjno metal radiometal odabran iz grupe koja se sastoji od 68Ga, 64Cu, 86Y, 90Y, 89Zr, 111In, 99mTc, 177Lu, 153Sm, 186Re, 188Re, 67Cu, 225Ac, 213Bi, 212Bi, 212Pb, 67Ga, 203Pb, 47Sc i 166Ho.
4. Spoj formule (I) za uporabu u liječenju jednog ili više tumora ili stanica koje eksprimiraju membranski antigen specifičan za prostatu (PSMA), naznačeno time, što spoj formule (I) sadrži:
[image]
pri čemu:
Z je tetrazol ili CO2Q;
Q je H ili protektivna grupa, pri čemu je protektivna grupa odabrana iz grupe koja se sastoji od benzila, p-metoksibenzila (PMB), tercijarnog butila (t-Bu), metoksimetila (MOM), metoksietoksimetila (MEM), metiltiometila (MTM), tetrahidropiranila (THP), tetrahidrofuranila (THF), benziloksimetila (BOM), trimetilsilila (TMS), trietilsilila (TES), t-butildimetilsilila (TBDMS) i trifenilmetila (tritil, Tr);
m je cijeli broj odabran iz grupe koja se sastoji od 1, 2, 3, 4 i 5;
R je -CH2-R1;
R1 je odabran iz grupe koja se sastoji od supstituiranog arila, supstituiranog piridina i nesupstituiranog izohinolina;
L je linker odabran iz grupe koja se sastoji od C1-C6 alkilena i C3-C6 cikloalkilena, i arilena;
W je odabran iz grupe koja se sastoji od -NR2-(C=O)-, -NR2-(C=S)-, -(C=O)-NR2- i -(C=S)-NR2-; pri čemu u svakom pojavljivanju L i W mogu biti isti ili različiti;
R2 je H ili C1-C4 alkil;
n je cijeli broj odabran iz grupe koja se sastoji od 1, 2 i 3;
Ch je kelirajuće sredstvo odabrano iz grupe koja se sastoji od:
[image]
[image]
[image]
gdje navedeno kelirajuće sredstvo sadrži radiometal pogodan za radioterapiju;
i njegove farmaceutski prihvatljive soli.
5. Postupak za liječenje jednog ili više tumora ili stanica koje eksprimiraju membranski antigen specifičan za prostatu (PSMA) in vitro ili ex vivo, naznačen time, što postupak sadrži dovođenje u kontakt jednog ili više tumora ili stanica koje eksprimiraju PSMA in vitro ili ex vivo sa efikasnom količinom spoja formule (I), pri čemu spoj formule (I) sadrži:
[image]
gdje:
Z je tetrazol ili CO2Q;
Q je H ili protektivna grupa, pri čemu je protektivna grupa odabrana iz grupe koja se sastoji od benzila, p-metoksibenzila (PMB), tercijarnog butila (t-Bu), metoksimetila (MOM), metoksietoksimetila (MEM), metiltiometila (MTM), tetrahidropiranila (THP), tetrahidrofuranila (THF), benziloksimetila (BOM), trimetilsilila (TMS), trietilsilila (TES), t-butildimetilsilila (TBDMS) i trifenilmetila (tritil, Tr);
m je cijeli broj odabran iz grupe koja se sastoji od 1, 2, 3, 4 i 5;
R je -CH2-R1;
R1 je odabran iz grupe koja se sastoji od supstituiranog arila, supstituiranog piridina i nesupstituiranog izokinolina;
L je linker odabran iz grupe koja se sastoji od C1-C6 alkilena i C3-C6 cikloalkilena, i arilena;
W je odabran iz grupe koja se sastoji od -NR2-(C=O)-, -NR2-(C=S)-, -(C=O)-NR2- i -(C=S)-NR2-; pri čemu u svakom pojavljivanju L i W mogu biti isti ili različiti;
R2 je H ili C1-C4 alkil;
n je cijeli broj odabran iz grupe koja se sastoji od 1, 2 i 3;
Ch je kelirajuće sredstvo odabrano iz grupe koja se sastoji od:
[image]
[image]
[image]
gdje navedeno kelirajuće sredstvo sadrži radiometal pogodan za radioterapiju;
i njegove farmaceutski prihvatljive soli.
6. Spoj za uporabu prema patentnom zahtjevu 4 ili postupak prema patentnom zahtjevu 5, naznačen time, što je R1 odabrano iz grupe koja se sastoji od:
[image]
gdje je X nezavisno Br ili I.
7. Spoj za uporabu prema bilo kojem od patentnih zahtjeva 4-6 ili postupak prema bilo kojem od patentnih zahtjeva 5-6, naznačen time, što kelirajuće sredstvo sadrži radiometal odabran iz grupe koja se sastoji od 68Ga, 64Cu, 86Y, 90Y, 89Zr, 111In, 99mTc, 177Lu, 153Sm, 186Re, 188Re, 67Cu, 212Pb, 225Ac, 213Bi, 212Bi, 67Ga, 203Pb, 47Sc i 166Ho.
8. Spoj za uporabu prema bilo kojem od patentnih zahtjeva 4-7 ili postupak prema bilo kojem od patentnih zahtjeva 5-7, naznačen time, što je jedan ili više tumora ili stanice koje eksprimiraju PSMA odabrano iz grupe koja se sastoji od tumora ili stanice prostate, metastaziranog tumora ili stanice prostate, tumora ili stanice pluća, tumora ili stanice bubrega, glioblastoma, tumora ili stanice gušterače, tumora ili stanice mjehura, sarkoma, melanoma, tumora ili stanice dojke, tumora ili stanice debelog crijeva, germinativne stanice, feokromocitoma, tumora ili stanice jednjaka, tumora ili stanice želuca, i njihovih kombinacija.
9. Spoj za uporabu prema bilo kojem od patentnih zahtjeva 4-8 ili postupak prema bilo kojem od patentnih zahtjeva 5-8, naznačen time, što su jedan ili više tumora ili stanica koje eksprimiraju PSMA tumor ili stanica prostate.
10. Spoj za uporabu prema bilo kojem od patentnih zahtjeva 4-9 ili postupak prema bilo kojem od patentnih zahtjeva 5-9, naznačen time, što liječenje dovodi do inhibicije rasta tumora.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662311697P | 2016-03-22 | 2016-03-22 | |
EP21177643.0A EP3925952B1 (en) | 2016-03-22 | 2017-03-22 | Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20240215T1 true HRP20240215T1 (hr) | 2024-04-26 |
Family
ID=59899817
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20240215TT HRP20240215T1 (hr) | 2016-03-22 | 2017-03-22 | Sredstva sa visokim afinitetom za ciljani učinak na membranski antigen specifičan za prostatu za endoradioterapiju raka prostate |
HRP20211386TT HRP20211386T1 (hr) | 2016-03-22 | 2021-08-31 | Sredstva sa visokim afinitetom za ciljano djelovanje na membranski antigen specifičan za prostatu za endoradioterapiju raka prostate |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20211386TT HRP20211386T1 (hr) | 2016-03-22 | 2021-08-31 | Sredstva sa visokim afinitetom za ciljano djelovanje na membranski antigen specifičan za prostatu za endoradioterapiju raka prostate |
Country Status (27)
Country | Link |
---|---|
US (2) | US11458213B2 (hr) |
EP (2) | EP3925952B1 (hr) |
JP (3) | JP7073270B2 (hr) |
KR (3) | KR102396307B1 (hr) |
CN (2) | CN109311827B (hr) |
AU (1) | AU2017238181B2 (hr) |
BR (1) | BR112018069507A2 (hr) |
CA (1) | CA3018709A1 (hr) |
CL (1) | CL2018002683A1 (hr) |
CY (1) | CY1124487T1 (hr) |
DK (2) | DK3925952T3 (hr) |
ES (1) | ES2877572T3 (hr) |
FI (1) | FI3925952T3 (hr) |
HR (2) | HRP20240215T1 (hr) |
HU (1) | HUE055607T2 (hr) |
LT (2) | LT3925952T (hr) |
MX (1) | MX2018011519A (hr) |
PH (1) | PH12018502048A1 (hr) |
PL (2) | PL3433238T3 (hr) |
PT (2) | PT3433238T (hr) |
RS (2) | RS65188B1 (hr) |
RU (2) | RU2021115958A (hr) |
SA (1) | SA518400103B1 (hr) |
SI (2) | SI3925952T1 (hr) |
TR (1) | TR201813644T1 (hr) |
WO (1) | WO2017165473A1 (hr) |
ZA (1) | ZA201806389B (hr) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7231536B2 (ja) | 2016-08-10 | 2023-03-01 | キャンサー ターゲテッド テクノロジー エルエルシー | キレート化されたpsma阻害剤 |
EP3544960A1 (en) * | 2016-11-23 | 2019-10-02 | Cancer Targeted Technology LLC | Albumin-binding psma inhibitors |
EP3555627B1 (en) | 2016-12-14 | 2023-11-22 | Purdue Research Foundation | Fibroblast activation protein (fap)-targeted imaging and therapy |
WO2018204477A1 (en) | 2017-05-02 | 2018-11-08 | Cornell University | Methods and reagents for tumor targeting with greater efficacy and less toxicity |
US11478558B2 (en) | 2017-05-30 | 2022-10-25 | The Johns Hopkins University | Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer |
JP7317375B2 (ja) * | 2017-12-11 | 2023-07-31 | テクニシェ ユニバーシタット ミュンヘン | 画像化および内部放射線療法のためのpsmaリガンド |
EP3494999A1 (en) * | 2017-12-11 | 2019-06-12 | Technische Universität München | Psma ligands for imaging and endoradiotherapy |
EP3494998A1 (en) * | 2017-12-11 | 2019-06-12 | Technische Universität München | Glycosylated psma inhibitors for imaging and endoradiotherapy |
JP7376481B2 (ja) * | 2017-12-13 | 2023-11-08 | サイエンコンス アクスイェ セルスカプ | 鉛またはトリウム放射性核種に連結されたpsma標的化化合物を含む錯体 |
SG11202007180QA (en) * | 2018-02-06 | 2020-08-28 | Univ Heidelberg | Fap inhibitor |
MX2020008247A (es) | 2018-02-06 | 2021-02-26 | Univ Johns Hopkins | Urea-poliaminocarboxilatos radiohalogenados dirigidos a antígeno prostático específico de membrana (psma) para radioterapia de cáncer. |
EP3778592B1 (en) * | 2018-03-30 | 2023-04-26 | Futurechem Co., Ltd. | Psma-targeted radiopharmaceutical for diagnosing and treating prostate cancer |
WO2019240884A2 (en) * | 2018-04-27 | 2019-12-19 | University Of Iowa Research Foundation | Compositions for chelating metals at low temperatures |
BR112021005931A2 (pt) * | 2018-09-28 | 2021-06-29 | Universität Heidelberg | composto, complexo e composição farmacêutica |
RU2697519C1 (ru) * | 2018-10-15 | 2019-08-15 | Общество с ограниченной ответственностью "Изварино Фарма" | Средство пептидной природы, включающее псма-связывающий лиганд на основе производного мочевины, способ его получения и применение для получения конъюгата с лекарственным и диагностическим агентом |
WO2020139012A1 (ko) * | 2018-12-27 | 2020-07-02 | (주)퓨쳐켐 | 카르복시산이 도입된 psma-표적 화합물 및 그의 용도 |
US20230226227A1 (en) * | 2019-07-02 | 2023-07-20 | Advanced Accelerator Applications (Italy) Srl | Prostate specific membrane antigen (psma) ligands and uses thereof |
CN114096526A (zh) * | 2019-07-02 | 2022-02-25 | 诺华股份有限公司 | 前列腺特异性膜抗原(psma)配体及其用途 |
RU2713151C1 (ru) * | 2019-07-02 | 2020-02-04 | Общество с ограниченной ответственностью "Изварино Фарма" | Конъюгат флуоресцентного красителя с веществом пептидной природы, включающим псма-связывающий лиганд на основе производного мочевины для визуализации клеток, экспрессирующих псма, способ его получения и применения |
RU2730507C1 (ru) * | 2019-08-27 | 2020-08-24 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Соединение для диагностики опухолей, экспрессирующих псма, и композиция на его основе |
AU2021262479A1 (en) | 2020-04-29 | 2022-11-17 | Novartis Ag | Methods for radiolabelling PSMA binding ligands and their kits |
WO2022043558A1 (en) | 2020-08-31 | 2022-03-03 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
WO2022043557A1 (en) | 2020-08-31 | 2022-03-03 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
WO2022043556A1 (en) | 2020-08-31 | 2022-03-03 | Novartis Ag | Stable radiopharmaceutical composition |
WO2022101352A1 (en) | 2020-11-12 | 2022-05-19 | Abx Advanced Biochemical Compounds Gmbh | Ligands of prostate specific membrane antigen (psma) containing heteroaromatic linker building blocks |
US20240010623A1 (en) | 2020-11-19 | 2024-01-11 | Novartis Ag | Synthesis of prostate specific membrane antigen (psma) ligands |
MX2021005089A (es) * | 2021-04-30 | 2022-11-01 | Instituto Nac De Investigaciones Nucleares | Radiofarmacos basados en el acido ((r)-1-((6-hidrazinilnicotinoil) d-alanil)pirrolidin-2-il)boronico (hynic-ifap) para la deteccion de la sobreexpresion de la proteina de activacion de fibrolastos. |
AU2022293573A1 (en) * | 2021-06-17 | 2023-12-14 | Mayo Foundation For Medical Education And Research | Methods and materials for combining biologics with multiple chelators |
KR20230050552A (ko) * | 2021-10-07 | 2023-04-17 | (주)퓨쳐켐 | 가돌리늄 화합물 및 이를 포함하는 전립선암의 진단 및 치료용 약학적 조성물 |
WO2023152671A1 (en) | 2022-02-09 | 2023-08-17 | Novartis Ag | Pharmaceutical compositions comprising a 225-actinium-labelled complex and a bismuth sequestering agent |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3466928A1 (en) * | 2007-06-26 | 2019-04-10 | The Johns Hopkins University | Labeled inhibitors of prostate-specific membrane antigen (psma), biological evaluation, and use as imaging agents |
WO2009070302A1 (en) | 2007-11-30 | 2009-06-04 | The Johns Hopkins University | Prostate specific membrane antigen (psma) targeted nanoparticles for therapy of prostate cancer |
BRPI0922779A8 (pt) | 2008-12-05 | 2018-06-19 | Molecular Insight Pharm Inc | complexos de tecnécio e rênio-bis(heteroarila) e métodos de uso dos mesmos para inibir psma |
WO2010108125A2 (en) * | 2009-03-19 | 2010-09-23 | The Johns Hopkins University | Psma-targeting compounds and uses thereof |
US8926944B2 (en) | 2011-08-05 | 2015-01-06 | Molecular Insight Pharmaceuticals | Radiolabeled prostate specific membrane antigen inhibitors |
ES2941937T3 (es) * | 2011-11-30 | 2023-05-26 | Univ Johns Hopkins | Compuesto dirigido a PSMA y sus usos |
SG11201505477TA (en) | 2013-01-14 | 2015-08-28 | Molecular Insight Pharm Inc | Triazine based radiopharmaceuticals and radioimaging agents |
EP2862857A1 (en) | 2013-10-18 | 2015-04-22 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
GEP20237496B (en) * | 2013-10-18 | 2023-04-10 | Deutsches Krebsforsch | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
JP6749249B2 (ja) | 2014-05-06 | 2020-09-02 | ザ ジョンズ ホプキンズ ユニヴァーシティー | Psmaを標的としたイメージング及び放射線治療のための金属/放射性金属標識psma阻害剤 |
EP3183236B1 (en) | 2014-08-24 | 2022-04-20 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften | Method for the production of 18f-labeled active esters and their application exemplified by the preparation of a psma-specific pet-tracer |
EP3212610B1 (en) * | 2014-10-30 | 2020-10-28 | Katholieke Universiteit Leuven | Methods for low temperature fluorine-18 radiolabeling of biomolecules |
US11520472B2 (en) * | 2015-09-24 | 2022-12-06 | Mitutoyo Corporation | Inspection program editing environment including integrated alignment program planning and editing features |
US10688200B2 (en) | 2015-12-31 | 2020-06-23 | Five Eleven Pharma Inc. | Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy |
-
2017
- 2017-03-22 EP EP21177643.0A patent/EP3925952B1/en active Active
- 2017-03-22 RU RU2021115958A patent/RU2021115958A/ru unknown
- 2017-03-22 ES ES17771028T patent/ES2877572T3/es active Active
- 2017-03-22 CA CA3018709A patent/CA3018709A1/en active Pending
- 2017-03-22 TR TR2018/13644A patent/TR201813644T1/tr unknown
- 2017-03-22 BR BR112018069507A patent/BR112018069507A2/pt unknown
- 2017-03-22 PL PL17771028T patent/PL3433238T3/pl unknown
- 2017-03-22 AU AU2017238181A patent/AU2017238181B2/en active Active
- 2017-03-22 RS RS20240205A patent/RS65188B1/sr unknown
- 2017-03-22 PL PL21177643.0T patent/PL3925952T3/pl unknown
- 2017-03-22 DK DK21177643.0T patent/DK3925952T3/da active
- 2017-03-22 KR KR1020187030310A patent/KR102396307B1/ko active IP Right Grant
- 2017-03-22 PT PT177710282T patent/PT3433238T/pt unknown
- 2017-03-22 RS RS20211071A patent/RS62274B1/sr unknown
- 2017-03-22 CN CN201780031580.2A patent/CN109311827B/zh active Active
- 2017-03-22 HR HRP20240215TT patent/HRP20240215T1/hr unknown
- 2017-03-22 DK DK17771028.2T patent/DK3433238T3/da active
- 2017-03-22 SI SI201731477T patent/SI3925952T1/sl unknown
- 2017-03-22 HU HUE17771028A patent/HUE055607T2/hu unknown
- 2017-03-22 KR KR1020227015010A patent/KR20220063298A/ko not_active Application Discontinuation
- 2017-03-22 LT LTEP21177643.0T patent/LT3925952T/lt unknown
- 2017-03-22 WO PCT/US2017/023508 patent/WO2017165473A1/en active Application Filing
- 2017-03-22 US US16/087,395 patent/US11458213B2/en active Active
- 2017-03-22 MX MX2018011519A patent/MX2018011519A/es unknown
- 2017-03-22 FI FIEP21177643.0T patent/FI3925952T3/fi active
- 2017-03-22 RU RU2018133693A patent/RU2749399C2/ru active
- 2017-03-22 LT LTEPPCT/US2017/023508T patent/LT3433238T/lt unknown
- 2017-03-22 EP EP17771028.2A patent/EP3433238B1/en active Active
- 2017-03-22 JP JP2018549808A patent/JP7073270B2/ja active Active
- 2017-03-22 PT PT211776430T patent/PT3925952T/pt unknown
- 2017-03-22 CN CN202210306552.XA patent/CN114716387A/zh active Pending
- 2017-03-22 SI SI201730908T patent/SI3433238T1/sl unknown
- 2017-03-22 KR KR1020237034341A patent/KR20230147751A/ko not_active Application Discontinuation
-
2018
- 2018-09-21 CL CL2018002683A patent/CL2018002683A1/es unknown
- 2018-09-24 PH PH12018502048A patent/PH12018502048A1/en unknown
- 2018-09-25 ZA ZA2018/06389A patent/ZA201806389B/en unknown
- 2018-09-25 SA SA518400103A patent/SA518400103B1/ar unknown
-
2021
- 2021-08-31 HR HRP20211386TT patent/HRP20211386T1/hr unknown
- 2021-09-13 CY CY20211100803T patent/CY1124487T1/el unknown
-
2022
- 2022-05-11 JP JP2022077992A patent/JP2022116028A/ja active Pending
- 2022-08-22 US US17/892,203 patent/US20230015736A1/en not_active Abandoned
-
2024
- 2024-01-11 JP JP2024002743A patent/JP2024050608A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20240215T1 (hr) | Sredstva sa visokim afinitetom za ciljani učinak na membranski antigen specifičan za prostatu za endoradioterapiju raka prostate | |
JP2019519467A5 (hr) | ||
FI103792B (fi) | Makrosyklisiä bifunktionaalisia kelaatinmuodostajayhdisteitä, niiden metallikomplekseja sekä näiden kompleksien vasta-ainekonjugaatteja | |
HRP20191620T1 (hr) | Grpr-antagonisti za otkrivanje, dijagnostiku i liječenje grpr-pozitivnog raka | |
HRP20171534T1 (hr) | Derivati fosfora kao inhibitori kinaza | |
AU2016237099C1 (en) | Method for producing novel nitrogen-containing compound or salt thereof, and production intermediate of same | |
IL266563B (en) | Heterocyclic compounds used as pdk1 inhibitors | |
AU2010260195B2 (en) | Process for production of heterodimers of glutamic acid | |
Akurathi et al. | Development and biological evaluation of 99mTc-sulfonamide derivatives for in vivo visualization of CA IX as surrogate tumor hypoxia markers | |
US20230136073A1 (en) | Novel nitrogen-containing compound or salt thereof, or metal complex thereof | |
NZ701478A (en) | Pyrrolobenzodiazepines | |
JP2015531371A5 (hr) | ||
DK2536691T3 (en) | BIFUNCTIONAL CHELATING AGENT | |
JP2019502675A5 (hr) | ||
WO2008151253A1 (en) | Hypoxia activated prodrugs of antineoplastic agents | |
CA3100319A1 (en) | Matrix metalloproteinase (mmp) inhibitors and methods of use thereof | |
RU2015140920A (ru) | Добавка для гидравлически схватывающихся составов | |
AU2012350147A1 (en) | Cage amine ligands for metallo-radiopharmaceuticals | |
JP2008537958A5 (hr) | ||
US5493046A (en) | Process | |
HUT67915A (en) | Process for producing sulphurated derivatives of imidazole | |
IE920762A1 (en) | Amide-chelates, their metal complexes as well as their use¹in diagnosis and treatment | |
Fu et al. | Synthesis and biological evaluation of 18F-labled 2-phenylindole derivatives as PET imaging probes for β-amyloid plaques | |
WO2019036839A1 (zh) | 泊马度胺衍生物及其制备方法 | |
EP3676256A1 (en) | Novel barbituric acid derivatives, their preparation and use thereof as leukocyte transmigration inhibitors and for treating inflammatory diseases, autoimmune diseases and cancer |